Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2320 - Genetic influence of EGFR-PI3K-mTOR pathway and other loci in triple-negative breast cancer


10 Oct 2016


Poster display


Carlos Cabrera


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


C. Cabrera1, M.J. Arranz2, M.L. Surralles Calnge3, A. Salas3, X. Tarroch3, L. Ibañez2, A. Garcia4, S. Gonzalez Jimenez1, M. Campayo1, L. Cirera1

Author affiliations

  • 1 Oncology And Hematology Department, Hospital Univeristari Mutua Terrassa, 08221 - Terrassa/ES
  • 2 Fundacio Docència I Recerca Mútua Terrassa, Hospital Univeristari Mutua Terrassa, 08221 - Terrassa/ES
  • 3 Pathology Department, Hospital Univeristari Mutua Terrassa, 08221 - Terrassa/ES
  • 4 Gynecology And Obstretics Department, Hospital Univeristari Mutua Terrassa, 08221 - Terrassa/ES


Abstract 2320


Breast cancer (BC) is the most frequent cancer in women. About 15% of all cases account for the most aggressive subtype: triple negative breast cancer (TNBC). TNBC biological heterogeneity has been explained in both gene expression profile studies and genome wide association studies (GWAS). Our study explores the role of single nucleotide polymorphisms (SNP) in TNBC. We hypothesized that new loci can confer risk and prognosis of TNBC, given its well-known tendency to genetic aberrations.


In this retrospective study, we genotyped a group of SNP in 111 paraffin-embedded tumor samples of patients diagnosed with TNBC (cases) and in 176 blood samples of healthy donors (controls). The SNP were selected from 5 genes (MAP3K1, PI3K, TERT, EGFR, and mTOR) known for their implication in TNBC and other types of cancer.


Univariate analysis with chi-square test comparing genotypic frequencies between cases and controls confirmed statistical significance in EGFR rs4947986 (p= 0.001) and TERT rs2736100 (p=


Our study found no prognostic significance of SNP for disease free survival (DFS) or overall survival (OS) in the multivariate analyses including TNM stage, axillary status, treatment (chemotherapy and/or radiotherapy) and age.

Our findings not only confirm the genetic influence of molecular pathways in EGFR, PI3K, mTOR and MAP3K1 but also reveal new loci for development of TNBC.

Having recognized new TERT and EGFR mutations in our cohort encourages us to keep unveiling plausible new pathways on carcinogenesis and treatment targets for TNBC. However, more translational studies are mandatory.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitari Mutua Terrassa-Oncology and Hematology Department


Hospital Universitari Mutua Terrassa


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings